1/ Another big day for COVID-19 vaccines! FDA panel votes to recommend emergency use authorization for Moderna’s mRNA vaccine.

@Moderna_tx CEO @Sbancel shares HOW they made a vaccine *in less than a year* w/ me + @omnivorousread on @a16z Bio Eats World

a16z.com/2020/12/18/mod…
2/ Within 48 hrs(!) of having a digital copy of the virus genome, Moderna designed a vaccine - the exact version now being shipped - without having access to the physical virus.

This is *the machine that made the vaccine*

We used to grow our vaccines; now we can print them.
3/ The tech works by delivering mRNA instructions for cells to make a protein. In this case, the vaccine is delivering instructions for making the SARS-CoV-2 spike protein (so our immune system learns to attack it).

@sbancel describes it as sorta like making chocolate mousse :)
4/ Based on Phase 3 data, this vaccine is ~95% effective.

Can you imagine knowing how important your work is, working non-stop, waiting for the data and approval? Bancel describes all this + the moment he shared the news with his family (spoiler alert: there was crying)
5/ (On a personal note, Stephane supported me throughout my own entrepreneurial journey, as both an informal mentor + board member of my startups. So I had a front-row seat watching him build Moderna, the company behind this vaccine. Thank you, @sbancel)
6/ Stephane represents the combo of qualities that will build the future of bio: an entrepreneur’s relentless drive + an engineer’s discipline. Vision, and a way to make it happen.
7/ Emergency use authorization will immediately release ~6 million doses; the US government has purchased 200 million doses through June 2021.

reuters.com/article/us-hea…
8/ mRNA vaccines are a bright light at the end of a long, dark tunnel. But we’re still in the tunnel—so stay safe, stay vigilant.
9/ The story of mRNA vaccines—and healthcare workers—is a story of care + ingenuity. This innovation shows that we’ve only begun scratching the surface of what the future can look like. Hope.

a16z.com/tag/vaccines/
10/ ...and it’s official! Moderna’s mRNA vaccine authorized by FDA for emergency use against COVID-19

fda.gov/news-events/pr…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Jorge Conde

Jorge Conde Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @JorgeCondeBio

31 May 19
1/ Recently $NVS announced a $2.1m gene therapy, the most expensive medicine in history. Gene therapies are potentially curative. How should we price them? How will we pay for them? Could a cure be considered a pre-existing condition? 🧬 💊
a16z.com/2019/05/30/cur…
2/ Rare disease therapies are expensive because: i) they treat devastating diseases, ii) patient pops are small, so biopharma recoups R&D investment w/ high price, iii) payors tolerate because limited risk of many patients in a given plan + limited # of new therapies to cover.
3/ Individually, rare diseases (by definition) affect few people; collectively, 30m Americans (1 in 10) suffer from one of 7000 rare diseases. There are now lots of gene therapies on the horizon for lots of rare diseases; many >$1m therapies in our future. How will we pay?
💰💰💰
Read 7 tweets
5 Jan 19
1/ A thought for early-stage bio companies on the eve of the upcoming #JPM19 networking bonanza in SF: Bio entrepreneurs, especially first-time founders, often underestimate the importance of analyzing and selecting potential disease areas
(thread 👇)
2/ Your resources are (probably) finite. Your platform may have broad potential but if your goal is to develop therapeutics (Tx) or diagnostics (Dx), you need a rigorous process/framework for selecting disease indications. It should be an early core competency for your company
3/ This is particularly important given how long, risky and expensive it can be to develop a new Tx or Dx. We’ve written previously on 16 pitfalls to avoid when building a computational Tx startup, many of which touch on this issue (especially #5) a16z.com/2018/04/30/bui…
Read 14 tweets
27 Dec 18
1/ Check out my talk from this year’s @a16z Summit, where I give a brief overview on the future of medicine. CliffsNotes thread 👇
2/ Our earliest medicines were discovered in nature; later, we learned to use tools like chemistry to develop our own novel molecules; and when we couldn’t synthesize complex proteins ourselves (like insulin), we harnessed biotechnology to coax bacteria to produce them for us
3/ But the frontier of medicine is moving beyond chemicals and proteins; we’re increasingly able to program living things like cells, genes and mircrobes to serve as therapies
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!